Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?
Oliver Findling, Johann Sellner
Drug Discovery Today (2020) Vol. 26, Iss. 2, pp. 416-428
Closed Access | Times Cited: 17

Showing 17 citing articles:

Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
Lutz Achtnichts, Barbara Jakopp, Michael Oberle, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1470-1470
Open Access | Times Cited: 44
Progress in the Application of Drugs for the Treatment of Multiple Sclerosis
Weipeng Wei, Denglei Ma, Lin Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 41
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
Johann Sellner, Paulus Rommer
Vaccines (2021) Vol. 9, Iss. 2, pp. 99-99
Open Access | Times Cited: 27
Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
Tobias Moser, Tjalf Ziemssen, Johann Sellner
Wiener Medizinische Wochenschrift (2022) Vol. 172, Iss. 15-16, pp. 365-372
Open Access | Times Cited: 16
Repeated iv anti‐CD20 treatment in multiple sclerosis: Long‐term effects on peripheral immune cell subsets
Julia Feige, Tobias Moser, Katja Akgün, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 2, pp. 450-465
Open Access | Times Cited: 3
Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis
Anja Steinmaurer, Isabella Wimmer, Thomas Berger, et al.
Current Pharmaceutical Design (2021) Vol. 28, Iss. 6, pp. 437-444
Closed Access | Times Cited: 23
SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
Lutz Achtnichts, А. К. Овчинников, Barbara Jakopp, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 341-341
Open Access | Times Cited: 12
Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data
Larissa Hauer, Johann Sellner
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 3915-3927
Open Access | Times Cited: 10
Oligodendrocyte Development and Regenerative Therapeutics in Multiple Sclerosis
Nadjet Gacem, Brahim Nait‐Oumesmar
Life (2021) Vol. 11, Iss. 4, pp. 327-327
Open Access | Times Cited: 13
Ifit2 restricts murine coronavirus spread to the spinal cord white matter and its associated myelin pathology
Madhav Sharma, Debanjana Chakravarty, Afaq Hussain, et al.
Journal of Virology (2023) Vol. 97, Iss. 8
Open Access | Times Cited: 4
Alemtuzumab treatment for multiple sclerosis in Austria: An observational long‐term outcome study
Tobias Moser, Fabian Foettinger, Wolfgang Hitzl, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 6, pp. 1442-1455
Open Access | Times Cited: 1
Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience
Julian Perneczky, Johann Sellner
Journal of Central Nervous System Disease (2022) Vol. 14
Open Access | Times Cited: 7
Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients
María José Zarzuelo, Cristina Pérez-Ramírez, Yasmín Cura, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 10, pp. 1032-1032
Open Access | Times Cited: 8
Einblicke in die Behandlung der Multiplen Sklerose mit Cladribin-Tabletten seit Beginn der COVID-19-Pandemie
Johann Sellner
psychopraxis neuropraxis (2021) Vol. 24, Iss. 6, pp. 340-347
Open Access | Times Cited: 1
Autoimmune neurology—a rapidly evolving field
Johann Sellner
Wiener Medizinische Wochenschrift (2023) Vol. 174, Iss. 1-2, pp. 1-3
Open Access
Ifit2 regulates murine-coronavirus spread to the spinal cord white matter and its associated myelin pathology
Madhav Sharma, Debanjana Chakravarty, Ajay Zalavadia, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Oral disease modifying therapies – A game changer for treatment decision in untreated patients with RRMS and CIS? – A swiss single center cross-sectional study
Sebastian Finkener, Lutz Achtnichts, Michaela Cervenakova, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 68, pp. 104396-104396
Closed Access
Page 1

Scroll to top